Resources
Did you mean
IVAX Corp. (546 results)
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Teva is The Clear Market Leader Since Its 2006 Purchase of IVAX States New Report Opportunities and Challenges for Generic Drugs In The UK 2007.
- M2 PRESSWIRE-2 July 2007-Research and Markets: Teva is The Clear Market Leader Since Its 2006 Purchase of IVAX States New Report Opportunities and Challenges for Generic Drugs In The UK 2007C1994-2007 M2 COMMUNICATIONS LTD RDATE:04072007 Dublin - Research and Markets ...
- Research articles 2007-07-02
- Human BioSystems Granted its Third Patent.
- M2 PRESSWIRE-12 May 2006-SessionsIR.com: Human BioSystems Granted its Third PatentC1994-2006 M2 COMMUNICATIONS LTD RDATE:12052006 Stocks in the News: Human BioSystems Inc. (OTC: HBSC), UnitedHealth Group Inc. (NYSE: UNH), Boston Scientific Corp. (NYSE: BSX), Teva Pharmaceutical Industries Inc. (NASDAQ: TEVA), Ivax Corp....
- Research articles 2006-05-12
- Teva Announces FTC Will Not File Objections to Effexor® XR Settlement
- JERUSALEM -- The Federal Trade Commission has notified Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and Wyeth (NYSE:WYE) that it will not file an objection with the United States District Court for the District of New Jersey to the proposed settlement of the patent litigation between Teva and Wyeth concerning Teva's...
- Research articles 2005-12-02
- IVAX Announces Tender Offer For 4.5% Convertible Senior Subordinated Notes Due 2008
- MIAMI -- IVAX Corporation, a wholly owned subsidiary of Teva Pharmaceutical Industries Limited ("Teva"), announced today that it has commenced an offer to repurchase any and all of its outstanding 4.5% Convertible Senior Subordinated Notes due 2008 (the "Notes"). The indenture governing the Notes requires IVAX to make the offer...
- Research articles 2006-02-22
- Teva and IVAX Decline 'Public Acquirer Fundamental Change' Option for IVAX' 1.5% Convertible Senior Notes due 2025
- JERUSALEM & MIAMI -- Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) and IVAX Corporation (AMEX:IVX) issued the following statement regarding IVAX' outstanding 1.5% Convertible Senior Notes due 2025, in connection with Teva's pending acquisition of IVAX:
- Research articles 2006-01-03
- IVAX and Teva Decline ``Public Acquirer Fundamental Change'' Option for IVAX' 1.5% Convertible Senior Notes Due 2025
- JERUSALEM, Israel & MIAMI -- Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) and IVAX Corporation (AMEX:IVX) (LSE:IVX.L) (WSE:IVX) issued the following statement regarding IVAX' outstanding 1.5% Convertible Senior Notes due 2025, in connection with Teva's pending acquisition of IVAX:
- Research articles 2006-01-03
- Teva and IVAX Issue Statement Regarding Elections by Holders of IVAX Convertible Notes
- JERUSALEM, Israel and MIAMI -- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and IVAX Corporation (AMEX: IVX) issued the following statement regarding election procedures for holders of IVAX' outstanding convertible notes, in connection with Teva's pending acquisition of IVAX:
- Research articles 2005-12-19
- Teva to acquire Ivax and LifeCell Corporation announces Q2 financial results.
- M2 PRESSWIRE-25 July 2005-US Financial Network: Teva to acquire Ivax and LifeCell Corporation announces Q2 financial resultsC1994-2005 M2 COMMUNICATIONS LTD RDATE:25072005 City of Industry, CA - Biotechnology industry news provided by Financial News USA (OTC: FNWU). LifeCell Corporation (Nasdaq: LIFC) ...
- Research articles 2005-07-25
- IVAX Receives Final Approval on Clozapine Tablet
- MIAMI -- IVAX Corporation (AMEX:IVX) (LSE:IVX.L) (WSE:IVX) announced today that it has received final approval from the U.S. Food and Drug Administration FDA for its Abbreviated New Drug Application ANDA for clozapine tablets USP, 200 mg. This product will be sold through IVAX' wholly owned subsidiary, IVAX Pharmaceuticals, Inc. Clozapine...
- Research articles 2005-12-19
- IVAX Announces Tender Offer for 4.5% Convertible Senior Subordinated Notes Due 2008
- MIAMI -- IVAX Corporation (AMEX:IVX) (LSE:IVX.L) (WSE:IVX), announced today that it has commenced an offer to repurchase any and all of its outstanding 4.5% Convertible Senior Subordinated Notes due 2008 (the "Notes"). The indenture governing the Notes requires IVAX to make the offer as a result of the approval by...
- Research articles 2005-11-23
- Ivax Corp
- Miami-based pharmaceutical giant Ivax Corp. was acquired by Teva Pharmaceutical Industries Ltd. of Tel Aviv, Israel for $7.4 billion. The merger gives TEVA operations in more than 50 countries and approximately 25,000 employees. Ivax was one of South Florida's few public Fortune 500 firms.
- Research articles 2005-09-01
- IVAX to Present at the Twenty Sixth Annual Goldman Sachs Global Healthcare Conference
- MIAMI -- IVAX Corporation (AMEX:IVX) (LSE:IVX.L) (WSE:IVX) is scheduled to make a presentation Tuesday, June 14, 2005, at 2:00 PM Pacific Time (5:00 PM Eastern Time) at the Twenty Sixth Annual Goldman Sachs Global Healthcare Conference being held at the Ritz Carlton Laguna Niguel in Dana Point, California. Neil Flanzraich,...
- Research articles 2005-06-13
- Court Grants Depomed's Motion for Summary Judgment of Patent Infringement Against IVAX
- Court Rejects All Summary Judgment Motions From IVAX
- Research articles 2007-12-13
- Ivax receives approval for generic Pletal and Econ labs announces Q4 results.
- M2 PRESSWIRE-2 March 2005-FNWU: Ivax receives approval for generic Pletal and Econ labs announces Q4 resultsC1994-2005 M2 COMMUNICATIONS LTD RDATE:02032005 City of Industry, CA - Biotechnology industry news provided by Financial News USA (OTC: FNWU). Ivax Corp. (Nasdaq: IVX) said the...
- Research articles 2005-03-02
- A Company Review of IVAX Corporation Covering 40 Deals Made and Its Subsidiaries with 43 Partnering Companies
- DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c26870) has announced the addition of IVAX Corporation Deals Briefing to their offering
- Research articles 2005-11-10
- IVAX Shareholders Overwhelmingly Elect to Receive Stock Consideration in Teva Merger
- MIAMI -- At the request of The American Stock Exchange, IVAX Corporation (AMEX:IVX) (LSE:IVX.L) (WSE:IVX) announced today that an overwhelming majority of shareholders who made their elections prior to yesterday's deadline for making a cash or stock election under the merger agreement elected to receive stock consideration (0.8471 of a...
- Research articles 2006-01-25
- IVAX Responds to U.S. District Court Ruling on Clarithromycin ER
- MIAMI -- IVAX Corporation (AMEX:IVX) (LSE:IVX.L) (WSE:IVX), commenting upon the U.S. District Court for the District of Northern Illinois decision to grant Abbott Laboratories Inc.'s motion for a preliminary injunction against sales by Teva Pharmaceutical Industries Ltd. of its generic version of extended release antibiotic BiaxinR, states that this decision...
- Research articles 2005-06-06
- IVAX To Present At The Friedman Billings Ramsey 9th Annual Growth Conference
- MIAMI -- IVAX Corporation (AMEX:IVX) (LSE:IVX.L) (WSE:IVX) is scheduled to make a presentation Wednesday, June 1, 2005, at 10:20 AM Eastern Time at the Friedman Billings Ramsey 9th Annual Growth Conference being held at the Millennium Broadway Hotel in New York. Neil Flanzraich, vice chairman and president of IVAX Corporation,...
- Research articles 2005-05-26
- IVAX To Present At The CIBC World Markets Annual Biotechnology And Specialty Pharmaceuticals Conference
- MIAMI -- IVAX Corporation (AMEX:IVX) (LSE:IVX.L) (WSE:IVX) is scheduled to make a presentation Tuesday, April 5, 2005, at 4:15 PM Eastern Time at the CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference being held at The Millennium Broadway Hotel in New York City. Neil Flanzraich, vice chairman and president...
- Research articles 2005-04-01
- IVAX Receives Final Approval for Fluticasone Nasal Spray In UK
- MIAMI -- IVAX Corporation (AMEX:IVX) (LSE:IVX.L) (WSE:IVX) received final Marking Authorization approval from the Medicine and Healthcare Products Regulatory Agency for fluticasone nasal spray. Fluticasone is the generic equivalent of FlixonaseR (known in the U.S. as FlonaseR) and marketed by GlaxoSmithKline for the treatment of rhinitis. IVAX' generic equivalent of...
- Research articles 2005-05-13
- << Previous
- page 1 of 28
- Next >>
Content Types
Refining Tags
- FDA (17 results)
- merger (16 results)
- stock (15 results)
- health care (15 results)
- Pharmaceutical Company (12 results)
- acquisition (12 results)
- shareholder (12 results)
- agreement (11 results)
- tablet (9 results)
- FINANCE (9 results)
- sales (9 results)
- FTC (7 results)
- Bristol-Myers Squibb Co. (7 results)
- Nasdaq Stock Market Inc. (6 results)
- revenue (6 results)
- Company (6 results)
- marketing (5 results)
- board (4 results)
- Manufacturing (4 results)
- patent (4 results)
- Teva (4 results)
- net income (4 results)
- Investment (4 results)
- biotechnology (4 results)
- financial (4 results)
- Raymond James Financial Inc. (3 results)
- FPL Group Inc. (3 results)
- generic (3 results)
- Benefits (3 results)
- Webcast (3 results)
- board of directors (3 results)
- WCI Communities Inc. (3 results)
- INTERNET (3 results)
- IBM Lotus Notes (3 results)
- negotiation (3 results)
- Business Wire (3 results)
- UBS AG (3 results)
- Salomon Smith Barney (3 results)
- Lehman Brothers Inc. (3 results)
- Elizabeth Arden Inc. (3 results)
